Replies to post #72622 on Vivos Inc (RDGL)

[Luckysevens]

Y90 is already used and works

[Drugdoctor]

Phase I testing of a drug is ANIMAL STUDIES, therefore testing this drug for Vet. use, accomplishes 2 things... It will allow revenue generation by using in animals, while the Phase II and Phase III HUMAN TRIALS are conducted...

Look at the last line of this PR..

Vivos Inc Sets the Stage for the Introduction of IsoPet® (RadioGel™) to the Veterinarian Community
Richland, WA, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) finalizes its plan to introduce IsoPet® to the veterinarian community.

IsoPet® was designated as a device by the FDA and the Center for Veterinary Medicine has reviewed Vivos’ labeling and instructions for use for treating feline and canine sarcomas. This means that we have the green light to sell our product commercially for veterinary use. We believe that it is prudent to first complete the clinical study currently underway at the University of Missouri using IsoPet® to treat canine sarcomas. We are projecting the IsoPet® product debut by October of this year to allow time to collect more data on this indication for use.

The first product introductory step was recently accomplished by Dr. Alice Villalobos, Chair of our Veterinary Medicine Advisory Board. She has just published the 2nd edition of her book entitled, Canine and Feline Geriatric Oncology: Honoring the Human-Animal Bond. It is considered the “Bible” of Veterinary Oncology and features IsoPet®/RadioGel in three separate places.

An important vehicle for engaging thought leaders and early adopters in the veterinary community is through professional society conferences. The two premier conferences are annual meetings of the Veterinary Cancer Society (VCS) and the American College of Veterinary Radiology (ACVR). Attendance at these conferences will allow us to reach hundreds of veterinarians across the country and internationally.

Dr. Charlie Maitz, our principal investigator for canine sarcoma at the University of Missouri, will deliver a key-note presentation on the State of the Art of the Therapeutic use of Nuclear Medicine at the ACVR annual meeting in October 2018. He is anxious to discuss IsoPet in that important forum.
Vivos Inc is a bronze contributor and will have a booth at the annual VCS conference in October 2018. The VCS has just confirmed that our paper was accepted. It will summarize our therapies of feline sarcoma at Washington State University and canine soft tissue sarcomas at the University of Missouri. Dr. Janean Fidel from Washington State University, Dr. Charles Maitz from the University of Missouri and Dr. Darrell Fisher are co-authors. As a co-author and a member of the VCS I will be presenting the paper. I am also the introductory speaker for another presentation. This will be the first wide exposure of the veterinarian community to IsoPet.
Dr. Philip Bergman, a Director at VCA, one of our potential private clinic consortium partners, emphasized the importance of publishing in the VCS proceedings.

Mike Korenko, Vivos CEO, said, “Our intent is to use the VCS conference to identify a list of initial users of IsoPet®. We plan to select the optimum candidates in each of our targeted regions across the United States. We will offer to provide certification training and assist them in obtaining their radioactive material handling licenses. I am excited to be taking this important step. The animal testing has a dual purpose. It is also a key pre-clinical test to support human skin cancer therapy.”

https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1141383

[Luckysevens]

Here’s the link to information you’re looking for http://www.pnas.org/content/97/4/1802/tab-article-info